Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy

BACKGROUND: Several anti-viral drugs have demonstrated efficacy in preventing Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients. The recently approved valganciclovir is the most commonly used and most expensive drug for CMV prevention. The safety and efficacy data have been d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalil, Andre C., Freifeld, Alison G., Lyden, Elizabeth R., Stoner, Julie A.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677673/
https://www.ncbi.nlm.nih.gov/pubmed/19436751
http://dx.doi.org/10.1371/journal.pone.0005512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677673/
https://www.ncbi.nlm.nih.gov/pubmed/19436751
http://dx.doi.org/10.1371/journal.pone.0005512

Ejemplares similares